RamyAlyMahmoudMDMPH

Aerospace Medicine, Public Health & General Preventive Medicine

CEO, Optinose (NASDAQ: OPTN)

Dr. Mahmoud is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

National Capital Consortium Public Health and General Preventive MedicineResidency, Public Health and General Preventive Medicine, 1992 - 1994
Harvard School of Public HealthMPH, Health Policy & Management, 1992 - 1993
Harvard Medical SchoolFellowship, Clinical Effectiveness, 1992 - 1992
United States Army School of Aviation MedicineFS, 1991 - 1991
National Capital ConsortiumResidency, Internal Medicine, 1987 - 1990
University of Miami Leonard M. Miller School of MedicineClass of 1987

PA State Medical License 1997 - 2024
FL State Medical License 1990 - 2000
VA State Medical License 1990 - 1994
LA State Medical License 1987 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Preventive Medicine Public Health & General Preventive Medicine

PubMed

EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials.
Sarah K Wise, Nithin D Adappa, Rakesh K Chandra, Greg E Davis, Mahboobeh Mahdavinia
International Forum of Allergy & Rhinology. 2024-12-01
8 citations
Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2).
James N Palmer, Nithin D Adappa, Rakesh K Chandra, Greg E Davis, Mahboobeh Mahdavinia
The Journal of Allergy and Clinical Immunology. in Practice. 2024-04-01
5 citations
Efficacy of the exhalation delivery system with fluticasone in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery.
Randall A Ow, Zachary M Soler, Raj Sindwani, Donald A Leopold, Jivianne T Lee
International Forum of Allergy & Rhinology. 2023-01-01

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCEMay 4th, 2023
Optinose Submits Supplemental New Drug Application for XHANCE Label ExpansionFebruary 21st, 2023
Investors Gain a Breath of Fresh Air from Ph. 3 CS Trial ResultsJune 14th, 2022
Join now to see all

American College of Physicians - ACP
Fellow
American College of Preventive Medicine - ACPM
Member
American Medical Association - AMA
Member
Association of Military Surgeons of the United States
Member
International Society for CNS Clinical Trials and Methodology
Founding Member, Past President